Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

4.0%

1 terminated out of 25 trials

Success Rate

80.0%

-6.6% vs benchmark

Late-Stage Pipeline

8%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed with results

Key Signals

2 with results80% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (15)
P 1 (1)
P 2 (5)
P 3 (1)
P 4 (1)

Trial Status

Recruiting12
Not Yet Recruiting8
Completed4
Terminated1

Trial Success Rate

80.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT07376018Not ApplicableNot Yet Recruiting

Ketogenic Diet and Neuromodulation in Treatment Resistant Depression

NCT07623135Phase 3RecruitingPrimary

Lumateperone for Late-Life Depression

NCT07741981Not ApplicableNot Yet Recruiting

Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment

NCT07563868Not ApplicableRecruitingPrimary

Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression

NCT07227103Phase 2Not Yet Recruiting

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

NCT05952674Not ApplicableRecruitingPrimary

Treatment Resistant Depression and Vagus Nerve Stimulation

NCT06783361Not ApplicableCompletedPrimary

Accelerated Transcranial Magnetic Stimulation in Treatment-Resistant Depressed Patients

NCT07603804Not ApplicableRecruiting

Accelerated iTBS for Major Depression

NCT06682299Not ApplicableTerminatedPrimary

Maintenance TMS in Treatment Resistant Depression

NCT07080723Phase 4RecruitingPrimary

Algorithm Guided Treatment Versus Treatment as Usual (TAU) for Patients With Treatment Resistant Depression

NCT07247006Phase 2Not Yet RecruitingPrimary

Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression

NCT07146503Recruiting

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

NCT07329153Not ApplicableNot Yet RecruitingPrimary

Neuronavigated aiTBS for TRD

NCT07217223Not ApplicableRecruitingPrimary

Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study

NCT07324070Not ApplicableRecruiting

Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression

NCT07307768Phase 1Not Yet RecruitingPrimary

Ketamine Biomarker Validation

NCT07287839Phase 2Not Yet RecruitingPrimary

Parcel-guided rTMS for Major Depressive Disorder

NCT06773949Not ApplicableRecruiting

Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression

NCT07264452Not ApplicableRecruitingPrimary

Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst Stimulation in Patients With Treatment-Resistant Depression

NCT06668571Phase 2Recruiting

Intravenous Ketamine for Treatment-Resistant Depression

Scroll to load more

Research Network

Activity Timeline